Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Reform Should Be PhRMA Priority, HHS Secretary Thompson Says

Executive Summary

Passage of a Medicaid reform bill would do more to improve the pharmaceutical industry's image than a Medicare prescription drug benefit, HHS Secretary Thompson maintained during the PhRMA annual meeting in Naples, Fla. March 29

You may also be interested in...



SARS Infects Rx Industry: Vaccines Tested Against Virus; Antivirals Donated

GlaxoSmithKline, Wyeth, Merck and Aventis-Pasteur have been asked by HHS to test their vaccines against coronavirus in an effort to help find a prevention for severe acute respiratory syndrome

SARS Infects Rx Industry: Vaccines Tested Against Virus; Antivirals Donated

GlaxoSmithKline, Wyeth, Merck and Aventis-Pasteur have been asked by HHS to test their vaccines against coronavirus in an effort to help find a prevention for severe acute respiratory syndrome

Medicare Rx Funding Will Exceed $400 Bil., Breaux Predicts; War No Obstacle

Senate Medicare Rx legislation is likely to exceed the $400 bil. in funding set aside for the program by President Bush, Sen. John Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 28 in Naples, Fla

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel